ClinicalTrials.gg
Status unknownNCT04439890Updated Jun 19, 2020

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

A Phase 3 interventional study of Anlotinib hydrochloride capsule and Carboplatin injection in Advanced Non-squamous Cell Non-small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 59 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-19.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2019, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing catequentinib hydrochloride in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 3 under way, none of them phase 3. catequentinib hydrochloride · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 17
369 · median 46
Started
2019
with 5 others
Phase 3
3 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
3 of 17
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 17 studies testing catequentinib hydrochloride in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2019, is one of 3 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 17 studies testing catequentinib hydrochloride in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About catequentinib hydrochloride

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing catequentinib hydrochloride in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.

03

Conditions studied

  • Advanced Non-squamous Cell Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Local advanced (stage IIIB / ⅢC), or recurrent (stage IV) non-squamous cell non-small cell lung cancer, has at least one .

      1. EGFR, ALK, and ROS1 test results are negative. 3. (ECOG) performance status of 0 or 1, ≥ 12 weeks.
      1. Has not received systemic anti-tumor treatment for advanced disease. 5.Adequate organ system function. 6. Male or female subjects should agree to use an adequate method of starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ; No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization.
      1. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  • 1.Other histopathological types of non-small cell lung cancer. 2.Has received VEGF pathway targeted therapy including anlotinib and bevacizumab.

    1. Has multiple factors affecting oral medication. 4. Has symptomatic . 5. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
    1. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
    1. Has any severe and / or uncontrolled diseases. 8. Has any bleeding symptoms or treated with anticoagulants or vitamin K antagonists.

    9.Has received surgery, or unhealed wounds within 4 weeks before the first administration.

    1. Has hemoptysis within 28 days before randomization. 11. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear.
    1. Has arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident including , deep vein thrombosis and pulmonary embolism.
    1. Has psychotropic substances abuse or a mental disorder. 14. Have a history of immunodeficiency. 15. Has received allogeneic organ transplantation, hematopoietic stem cell transplantation or bone marrow transplantation.
    1. Has other . 17.Has participated in other anticancer drug clinical trials within 4 weeks. 18.According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
369 participants (estimated)

Study arms

  • Experimental
    Anlotinib hydrochloride capsule + chemotherapy

    Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).

    Drug: Anlotinib hydrochloride capsule · Drug: Carboplatin injection · Drug: Pemetrexed disodium f Injection

  • Placebo comparator
    Placebo + chemotherapy

    Placebo given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) + Carboplatin injection (AUC 5mg/mL/min, intravenous drip, on Day 1) + Pemetrexed disodium f Injection (500mg / m2, intravenous drip, on Day 1).

    Drug: Carboplatin injection · Drug: Pemetrexed disodium f Injection · Drug: Placebo

Interventions

  • Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

  • Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.

  • DrugPemetrexed disodium f Injection

    Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 48 weeks

Secondary outcomes

  1. Overall response rate (ORR) assessed by Independent Review Committee (IRC)

    Percentage of subjects achieving complete response (CR) and partial response (PR) based on IRC.

    Time frame: up to 48 weeks

  2. Overall survival (OS)

    OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.

    Time frame: up to 48 weeks

  3. Disease control rate(DCR)

    Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 48 weeks

  4. Disease of Response (DOR)

    DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.

    Time frame: up to 48 weeks

07

Study locations

59 of 59 sites recruiting
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230001, China
    Recruiting
    • Hui Zhao, Doctor · Contactdy61321157@163.com
    • Hui Zhao, Doctor · Principal investigator
  • Anhui Chest Hospital
    Hefei, Anhui 230011, China
    Recruiting
  • Yijishan Hospital of Wannan Medical College
    Wuhu, Anhui 242400, China
    Recruiting
    • Zhiwei Lu, Doctor · Contactsduzhiwei@sina.com
    • Zhiwei Lu, Doctor · Principal investigator
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing 100010, China
    Recruiting
  • Peking University Third Hospital
    Beijing, Beijing 100010, China
    Recruiting
  • The Sixth Medical Center of Chinese PLA General Hospital
    Beijing, Beijing 100010, China
    Recruiting
    • Zhihai Han, Doctor · Contacthanzhihai@souhu.com
    • Zhihai Han, Doctor · Principal investigator
  • Xuanwu Hospital of Capital Medical University
    Beijing, Beijing 100010, China
    Recruiting
  • Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
    Recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 431338, China
    Recruiting
    • Hong Chen, Doctor · Contact417335669@qq.com
    • Hong Chen, Doctor · Principal investigator
  • The Second Affiliated Hospital of Chinese PLA Army Medical University
    Chongqing, Chongqing 431338, China
    Recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
    Recruiting
    • Hongmei Yue, Doctor · Contact13893265368@163.com
    • Hongmei Yue, Doctor · Principal investigator
  • Gansu Wuwei Tumor Hospital
    Wuwei, Gansu 733000, China
    Recruiting
  • The Fifth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510010, China
    Recruiting
  • The First Affiliated Hospital of Guangdong Pharmaceutical University
    Guangzhou, Guangdong 510010, China
    Recruiting
    • Ying Ding, Doctor · Contactdy61321157@163.com
    • Ying Ding, Doctor · Principal investigator
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510289, China
    Recruiting
  • Meizhou People's Hospital
    Meizhou, Guangdong 514798, China
    Recruiting
    • Guowu Wu, Doctor · Contactwwwflay@126.com
    • Guowu Wu, Doctor · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Qitao Yu, Doctor · Contactyqt178@163.com
    • Qitao Yu, Doctor · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
    Recruiting
  • Xingtai People's Hospital
    Xingtai, Hebei 540000, China
    Recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yan Yu, Doctor · Contactgpyuyan@163.com
    • Yan Yu, Doctor · Principal investigator
  • First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
    Recruiting
  • The First Affiliated Hospital of Xinxiang Medical College
    Xinxiang, Henan 455001, China
    Recruiting
    • Hongrui Niu, Doctor · Contact1163458431@qq.com
    • Hongrui Niu, Doctor · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 475000, China
    Recruiting
    • Yanqiu Zhao, Doctor · Contact13938252350@163.com
    • Yanqiu Zhao, Doctor · Principal investigator
  • Huazhong University of Science Tongji Hospital, Tongji Medical College
    Wuhan, Hubei 430010, China
    Recruiting
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
    Recruiting
    • Chengping Hu, Doctor · Contacthuchengp@126.com
    • Chengping Hu, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 425001, China
    Recruiting
    • Jianhua Chen, Doctor · Contactcjh_1000@163.com
    • Jianhua Chen, Doctor · Principal investigator
  • Changzhou Second People's Hospital
    Changzhou, Jiangsu 213004, China
    Recruiting
    • Mingxia Yang, Doctor · Contactcougermx@126.com
    • Mingxia Yang, Doctor · Principal investigator
  • Lianyungang First People's Hospital
    Lianyungang, Jiangsu 222001, China
    Recruiting
    • Jiashu Li, Doctor · Contactlissm1118@sina.com
    • Jiashu Li, Doctor · Principal investigator
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 226691, China
    Recruiting
    • Jian Feng, Doctor · Contactjfeng68@126.com
    • Jian Feng, Doctor · Principal investigator
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221003, China
    Recruiting
    • Xiuping Du, Doctor · Contact1422363662@qq.com
    • Xiuping Du, Doctor · Principal investigator
  • Subei People's Hospital
    Yangzhou, Jiangsu 211400, China
    Recruiting
    • Xingxiang Xu, Doctor · ContactXuxxu63@sina.com
    • Xingxiang Xu, Doctor · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
  • The Second Hospital of Jilin University
    Changchun, Jilin 130011, China
    Recruiting
    • Yarong Li, Doctor · ContactDoctor.lyr@163.com
    • Yarong Li, Doctor · Principal investigator
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116001, China
    Recruiting
    • Yang Zhang, Doctor · Contactzydley@163.com
    • Yang Zhang, Doctor · Principal investigator
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Recruiting
    • Yunpeng Liu, Doctor · Contactcmu_trial@163.com
    • Yunpeng Liu, Doctor · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
    Recruiting
    • Weijun Bai, Doctor · Contact18900917878@163.com
    • Weijun Bai, Doctor · Principal investigator
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Neimenggu 010010, China
    Recruiting
    • Xiuhua Fu, Doctor · Contact1499521269@qq.com
    • Xiuhua Fu, Doctor · Principal investigator
  • Ningxia Medical University General Hospital
    Yinchuan, Ningxia 750001, China
    Recruiting
    • Wei Zhou, Doctor · Contactzhw0306@126.com
    • Wei Zhou, Doctor · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272000, China
    Recruiting
    • Shucheng Ye, Doctor · Contact18678766862@163.com
    • Shucheng Ye, Doctor · Principal investigator
  • Linyi Cancer Hospital
    Linyi, Shandong 277739, China
    Recruiting
    • Jianhua Shi, Doctor · Contactlyzlyygcp@163.com
    • Jianhua Shi, Doctor · Principal investigator
  • Tengzhou Central People's Hospital
    Tengzhou, Shandong 277500, China
    Recruiting
    • Lin Li, Doctor · Contactlilingtz@163.com
    • Lin Li, Doctor · Principal investigator
  • Fudan University Cancer Hospital
    Shanghai, Shanghai 200032, China
    Recruiting
  • Shanghai Chest Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Baohui Han, Doctor · Contact021-22200000-3138
    • Baohui Han, Doctor · Principal investigator
  • Linfen Central Hospital
    Linfen, Shanxi 314000, China
    Recruiting
    • Yanli Li, Doctor · Contact1270005400@qq.com
    • Yanli Li, Doctor · Principal investigator
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 300409, China
    Recruiting
    • Shouan Ren, Doctor · Contactrenshouan@163.com
    • Shouan Ren, Doctor · Principal investigator
  • Tangdu Hospital, The Fourth Military Medical University of PLA
    Xi'an, Shanxi 710038, China
    Recruiting
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 721001, China
    Recruiting
  • Dazhou Central Hospital
    Dazhou, Sichuan 635000, China
    Recruiting
    • Fudao Wu, Doctor · Contactwfde@163.com
    • Fudao Wu, Doctor · Principal investigator
  • Tianjin Chest Hospital
    Tianjin, Tianjin 300010, China
    Recruiting
    • Xun Zhang, Doctor · Contactzhangxun69@163.com
    • Xun Zhang, Doctor · Principal investigator
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300011, China
    Recruiting
    • Diansheng Zhong, Doctor · Contactzhongdsh@hotmail.com
    • Diansheng Zhong, Doctor · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
    • Dingzhi Huang, Doctor · Contactdingzhih72@163.com
    • Dingzhi Huang, Doctor · Principal investigator
  • Affiliated Tumor Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830011, China
    Recruiting
    • Zhigang Han, Doctor · Contact1378213986@qq.com
    • Zhigang Han, Doctor · Principal investigator
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650011, China
    Recruiting
    • Gaofeng Li, Doctor · Contactligaofenghl@126.com
    • Gaofeng Li, Doctor · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310002, China
    Recruiting
    • Xinmin Yu, Doctor · Contactyuxm@zjcc.org.cn
    • Xinmin Yu, Doctor · Principal investigator
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
    Recruiting
    • Jianying Zhou, Doctor · ContactDrzjy@163.com
    • Jianying Zhou, Doctor · Principal investigator
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
  • Ruian People's Hospital
    Ruian, Zhejiang 325000, China
    Recruiting
    • Zongxiao Shangguan, Doctor · Contactsangxao0707@163.com
    • Zongxiao Shangguan, Doctor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Jun 2021, 21 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 21 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 19, 2020
StartActual
Aug 8, 2019
Primary completionEst.
Jun 1, 2021
CompletionEst.
Dec 31, 2021
Last update
Jun 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04439890
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Aug 8, 2019
Primary completion
Jun 1, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Jun 19, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catequentinib hydrochloride

Start the discussion